Core Viewpoint - The A-share market is entering a period of intensive new stock offerings, with five companies available for subscription this week from October 13 to October 17, including Marco Polo, Chao Ying Electronics, He Yuan Bio, Xi'an Yicai, and Biobetter [1] Group 1: Marco Polo - Marco Polo is one of the largest manufacturers and sellers of building ceramics in China, with major brands including "Marco Polo Tiles" and "Weimei LD Ceramics" [2] - The company has five production bases located in Dongguan, Qingyuan, Fengcheng, Chongqing, and Tennessee, USA, focusing on both glazed and unglazed tiles [2] - Projected revenues for 2022 to 2024 are 8.661 billion, 8.925 billion, and 7.324 billion yuan, with net profits of 1.514 billion, 1.353 billion, and 1.327 billion yuan respectively [2] - The funds raised will be used for various smart manufacturing upgrades and capacity enhancement projects [2] Group 2: He Yuan Bio - He Yuan Bio is an innovative biopharmaceutical company focused on original innovation, with a leading global rice recombinant protein expression system [3] - The company has developed a third-generation technology platform achieving 20-30g/kg expression levels of human albumin, with several products in various stages of clinical research [3][4] - Projected revenues for 2022 to 2024 are 13 million, 24 million, and 25 million yuan, with net losses of 144 million, 187 million, and 151 million yuan respectively [3] Group 3: Chao Ying Electronics - Chao Ying Electronics specializes in the research, production, and sales of printed circuit boards (PCBs), with applications in automotive electronics, displays, storage, and consumer electronics [5] - The company has established stable partnerships with major global automotive suppliers and display manufacturers [5][6] - Projected revenues for 2022 to 2024 are 3.514 billion, 3.656 billion, and 4.124 billion yuan, with net profits of 141 million, 266 million, and 276 million yuan respectively [6] Group 4: Xi'an Yicai - Xi'an Yicai focuses on the research, production, and sales of 12-inch silicon wafers, ranking first in mainland China and sixth globally [7] - The company has the highest number of authorized domestic and international invention patents in the 12-inch silicon wafer sector [7] - Projected revenues for 2022 to 2024 are 1.055 billion, 1.474 billion, and 2.121 billion yuan, with net losses of 412 million, 578 million, and 738 million yuan respectively [7][8] Group 5: Biobetter - Biobetter is a biopharmaceutical company focused on innovative drug development for major diseases, with several products in various stages of clinical trials [9] - The company has a core product, BEBT-908, that has been approved for market, while others are in different phases of clinical trials [9][10] - Projected net losses for 2022 to 2024 are 188 million, 173 million, and 56 million yuan respectively [10][11]
本周，每天一只新股申购→
Zheng Quan Shi Bao·2025-10-13 01:48